Labiotech.eu

News and Trends 13 Jul 2022

Report says tech talent is hard to find

Randstad Sourceright’s 2022 life sciences and pharma Talent Trends report finds a third of C-suite and human capital leaders in the life sciences and pharmaceuticals sector say talent scarcity is a major pain point for the sector, which is hiring extensively this year. With demand for life sciences products expected to grow faster than the […]

July 13, 2022 - 4 minutesmins - By Jim Cornall

In Depth 13 Jul 2022

The biggest European biotech investments in June 2022

Oncology and AI-guided drug discovery firms roped in the biggest biotech investments in Europe in June 2022. The leading private rounds went to companies including ImCheck Therapeutics, MiroBio and Charm Therapeutics. In June 2022, we saw bigger private biotech investments in Europe than in May. ImCheck Therapeutics took the top spot; the firm raised an […]

July 13, 2022 - 3 minutesmins - By Jonathan Smith

antibody drug conjugate adc small cancer treatment

News and Trends 12 Jul 2022

Legochem Bioscience signs agreement with Glycotope to develop cancer drug

A company from South Korea has signed a research collaboration and license agreement with a German business to develop a cancer fighting drug. Seoul-based Legochem Biosciences Inc and Berlin-based Glycotope GmbH will develop an antibody drug conjugate (ADC) by combining LBC’s technology with one of Glycotope’s investigational tumor targeting antibodies. ADCs are a class of […]

July 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Jul 2022

Spanish company, 3P Biopharmaceuticals, manufactures biomass to treat black fungus

A biomass to treat a difficult and evasive fungal infection with a high mortality rate has been manufactured by Spanish organization, 3P Biopharmaceuticals (3P). It created BSG005 biomass for its partner and client, Biosergen, a Norwegian biotechnology company that has just announced a phase 2 clinical trial of the product against mucormycosis – also known […]

July 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Jul 2022

First patient receives new immunotherapy drug for HIV in clinical trial

A new class of bispecific protein immunotherapy, being developed for patients with human immunodeficiency virus (HIV) infection, has been given to the first patient in a clinical trial. Immunocare Holdings plc, a UK-based, commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad […]

July 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Jul 2022

AI being used to perform molecular analysis of biopsies from bowel disease patients

Artificial intelligence will be used to perform molecular analysis of biopsies from unidentified Inflammatory Bowel Disease (IBD) patients in a bid to help those with immune diseases and cancer. Athos Therapeutics, a late-stage preclinical, California-based biotech company uses artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced this week (July 11) […]

July 12, 2022 - 2 minutesmins - By Liza Laws

organoids in a dish, drug development, patient relevant model

The organoid era: bringing patient-relevant preclinical models to the lab

Drug development is a lengthy and costly process that takes at least 10 years on average from drug discovery to commercialization, requiring billions of dollars in investment. However, over 90% of new drugs that are tested in clinical trials fail. Organoids — three-dimensional, patient-derived mini-organs in a dish — offer a solution to this challenge. […]

July 12, 2022 - 7 minutesmins - By Sudha Sundaram

Interview 12 Jul 2022

Where AI can’t go: PhoreMost’s quest to unearth protein degradation targets

Advances in the AI-powered simulation of proteins are making it easier than ever to discover new drugs. Neil Torbett, CEO of PhoreMost, outlines how the firm’s protein screening technology overcomes current limitations of protein structure predictions, with big applications in the emerging field of protein degradation. Proteins are a critical component to a cell’s activities, […]

July 12, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 12 Jul 2022

Endogena Therapeutics to start clinical stage with treatment for blindness caused by retinitis pigmentosa

Endogena Therapeutics Inc. has announced the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP). RP is a group of inherited diseases causing slow and progressive retinal degeneration and loss of vision, for which there is currently no treatment for […]

July 12, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 11 Jul 2022

Financing round of $21M completed for drug to treat autoimmune diseases

The first-round of financing to the tune of $21 million (€20.6 million), for a drug to treat autoimmune disease, has been completed between Precision Autoimmune Therapeutics (PAT) and CASI Pharmaceuticals. PAT will pay CASI a $5 million (€4.9 million) equivalent as the first instalment of the upfront payment of the sub-license agreement. In May this […]

July 11, 2022 - 3 minutesmins - By Liza Laws

News and Trends 11 Jul 2022

Treatment for cancer-associated thrombosis fast-tracked by FDA

A clinical-stage biotechnology company that develops therapies for cardiovascular and metabolic diseases today (July 11) announced it has been granted fast track designation by the US Food and Drug Administration (FDA) for a treatment for thrombosis associated with cancer. Anthos Therapeutics focuses on the development and commercialization of drugs and abelacimab is a new, highly […]

July 11, 2022 - 4 minutesmins - By Liza Laws

multiOmics Health metabolic disorders precision medicine

Opinion 11 Jul 2022

Precision medicine: the next big leap for metabolic disorders

Chronic metabolic disorders like type 2 diabetes and cardiovascular disease are a huge burden on healthcare systems, and their treatment is often fragmented and reliant on trial-and-error approaches. Rebecca Cripps and Robert Thong at MultiOmic Health explain how precision medicine is set to change the way we think about these disorders. Metabolic disorders constitute the […]

July 11, 2022 - 6 minutesmins - By External Contributor

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Report says tech talent is hard to find

The biggest European biotech investments in June 2022

Legochem Bioscience signs agreement with Glycotope to develop cancer drug

Spanish company, 3P Biopharmaceuticals, manufactures biomass to treat black fungus

First patient receives new immunotherapy drug for HIV in clinical trial

AI being used to perform molecular analysis of biopsies from bowel disease patients

The organoid era: bringing patient-relevant preclinical models to the lab

Where AI can’t go: PhoreMost’s quest to unearth protein degradation targets

Endogena Therapeutics to start clinical stage with treatment for blindness caused by retinitis pigmentosa

Financing round of $21M completed for drug to treat autoimmune diseases

Treatment for cancer-associated thrombosis fast-tracked by FDA

Precision medicine: the next big leap for metabolic disorders

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!